摘要： 半年前，华熙生物创始人、董事长兼总裁赵燕才重回权力中心，这个出生于云南昆明，把玻尿酸生意做到千亿市值的女强人，把刀刃向内掀起了一场铁腕 改革。 凤凰网科技《风暴眼》出品 华熙生物位于北京华熙国际中心的总部，正在酝酿一场风暴。 凤凰网科技了解到，多位员工于近日收到了HR的约谈，要求员工们接受一定赔偿离职，否则将转为外包。有员工告诉凤凰网科技，这次赔偿方案并不一 致，"有人是N+1，有人是N，有人甚至连N都拿不到"。 对于员工们来说，这场动荡并不意外。今年初开始，员工们发现许多同事开始从与华熙生物签订合同，转向外包公司，"说是外包公司，但我们查了下并 没有相关劳务派遣资质"。 紧接着在8月前后，越来越人接到了谈话，"公司的策略是即将把北京大部队迁往杭州，北京只保留部分业务，且会以顾问形式进行"，但多数员工已在北 京安家，等待大家的只剩下"被动离职"。 另一位刚离职的华熙生物员工也告诉凤凰网科技，之前公司是小调整，最近就是大的组织优化，"这么说吧，之前肌活和米蓓尔的团队都一百多人了，现 在只剩下十几个人了"，其表示，目前裁员赔偿均可以谈。 组织震荡，与一位铁娘子的回归密切相关。 半年前，华熙生物创始人、董事 ...

Core Viewpoint - Huaxi Biological has reported its worst semi-annual financial results since going public, with significant declines in both revenue and net profit, indicating a challenging period for the company [1][6]. Financial Performance - In the first half of 2025, Huaxi Biological's revenue was 2.26 billion yuan, a year-on-year decrease of 19.57% [2]. - The net profit attributable to shareholders was 220.85 million yuan, down 35.38% year-on-year, with a 45% decline in net profit after excluding non-recurring gains and losses [2][1]. - The company's total assets decreased by 0.97% compared to the previous year, while net assets attributable to shareholders increased by 3.27% [2]. Organizational Changes - The company is undergoing significant internal restructuring, with reports of major layoffs, particularly in the teams of its skincare brands, which have seen staff numbers drop from over a hundred to just a few dozen [2][24]. - The return of founder Zhao Yan has led to a wave of organizational changes, including the departure of over 10 senior executives and a shift towards a more entrepreneurial management style [4][28]. Market Position and Strategy - Huaxi Biological, once a leader in the hyaluronic acid market with a 44% global market share, has seen its competitive edge erode, leading to a decline in its skincare product sales [8][11]. - The company’s functional skincare products generated 4.61 billion yuan in sales in 2022, but this segment has faced a significant downturn, with a 31.62% year-on-year decline in 2024 [9][11]. - The company is shifting its focus from a reliance on influencer marketing to a more sustainable business model, as the previous strategies have become less effective in a competitive market [12][30]. Internal Challenges - Huaxi Biological is facing a crisis of trust internally, with allegations of financial misconduct and workplace bullying surfacing, further complicating its operational challenges [17][26]. - The company has implemented strict measures against corruption, demanding accountability from its staff and restructuring its management to restore confidence [21][28]. Future Outlook - While Zhao Yan's return has sparked hope for a turnaround, the company still faces significant challenges in a competitive market, with consumer preferences shifting away from hyaluronic acid products [30][32]. - The performance of Huaxi Biological in the coming quarters will be critical in determining the effectiveness of its restructuring efforts and market strategy [32].